Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov;41(11):3205-3230.
doi: 10.1007/s00345-023-04330-1. Epub 2023 Mar 11.

The role of perioperative chemotherapy for upper tract urothelial carcinoma patients treated with radical nephroureterectomy

Ugo Pinar  1 , Giorgio Calleris  2 , Elisabeth Grobet-Jeandin  3 , Pietro Grande  1 , Daniel Benamran  3 , Constance Thibault  4 , Paolo Gontero  2 , Morgan Rouprêt  1 , Thomas Seisen  5
Affiliations
Review

The role of perioperative chemotherapy for upper tract urothelial carcinoma patients treated with radical nephroureterectomy

Ugo Pinar et al. World J Urol. 2023 Nov.

Abstract

Purpose: To summarize evidence regarding the use of neoadjuvant (NAC) and adjuvant chemotherapy (AC) among patients treated with radical nephroureterectomy (RNU).

Methods: A comprehensive literature search of PubMed (MEDLINE), EMBASE and the Cochrane library was performed to identify any original or review article on the role of perioperative chemotherapy for UTUC patients treated with RNU.

Results: With regards to NAC, retrospective studies consistently suggested that it may be associated with better pathological downstaging (pDS) ranging from 10.8 to 80% and complete response (pCR) ranging from 4.3 to 15%, while decreasing the risk of recurrence and death as compared to RNU alone. Even higher pDS ranging from 58 to 75% and pCR ranging from 14 to 38% were observed in single-arm phase II trials. With regards to AC, retrospective studies provided conflicting results although the largest report from the National Cancer Database suggested an overall survival benefit in pT3-T4 and/or pN + patients. In addition, a phase III randomized controlled trial showed that the use of AC was associated with a disease-free survival benefit (HR = 0.45; 95% CI = [0.30-0.68]; p = 0.0001) in pT2-T4 and/or pN + patients with acceptable toxicity profile. This benefit was consistent in all subgroups analyzed.

Conclusions: Perioperative chemotherapy improves oncological outcomes associated with RNU. Given the impact of RNU on renal function, the rational is stronger for the use of NAC which impacts final pathology and potentially prolongs survival. However, the level of evidence is stronger for the use of AC that has been proven to decrease the risk of recurrence after RNU with a potential survival benefit.

Keywords: Adjuvant; Chemotherapy; Neoadjuvant; Radical nephroureterectomy; Recurrence; Renal pelvis; Survival; Ureter; Urothelial carcinoma.

PubMed Disclaimer

References

    1. Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69:7–34. https://doi.org/10.3322/caac.21551 - DOI - PubMed
    1. Soria F, Shariat SF, Lerner SP et al (2017) Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol 35:379–387. https://doi.org/10.1007/s00345-016-1928-x - DOI - PubMed
    1. Lughezzani G, Jeldres C, Isbarn H et al (2010) Temporal stage and grade migration in surgically treated patients with upper tract urothelial carcinoma. BJU Int 105:799–804. https://doi.org/10.1111/j.1464-410X.2009.08818.x - DOI - PubMed
    1. Margulis V, Shariat SF, Matin SF et al (2009) Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration. Cancer 115:1224–1233. https://doi.org/10.1002/cncr.24135 - DOI - PubMed
    1. Rouprêt M, Babjuk M, Compérat E et al (2018) European association of urology guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol 73:111–122. https://doi.org/10.1016/j.eururo.2017.07.036 - DOI - PubMed

MeSH terms

LinkOut - more resources